HUTCHMED starts HMPL-A830 cancer trial
- HUTCHMED began a global Phase Ia trial of HMPL-A830, an investigational treatment for patients with advanced solid tumors.
- The first patient received a dose in China on September 24, 2026, as the company evaluates safety and tolerability.
- HUTCHMED said a GSK subsidiary will hold development and commercialization rights outside Mainland China, Hong Kong, Macau, and Taiwan under a prior agreement.
HUTCHMED (NASDAQ:HCM) initiated a global Phase Ia clinical trial of HMPL-A830 in patients with advanced solid tumors, with the first patient receiving a dose in China on September 24, 2026.
The first-in-human, multicenter study is enrolling patients with unresectable, advanced, or metastatic solid tumors as the company evaluates the safety profile and appropriate dosing of the investigational therapy.
The Phase Ia portion of the study will assess safety and tolerability while determining the maximum tolerated dose and recommended dose for expansion, with a later expansion stage planned to evaluate safety and preliminary anti-tumor activity in selected solid tumors.
HUTCHMED develops medicines focused on oncology and immunology, including targeted therapies designed to address cancer-related biological pathways.
The company said its subsidiary will manage the global Phase I program, while a GSK (NYSE:GSK) subsidiary received development and commercialization rights outside Mainland China, Hong Kong, Macau, and Taiwan under an exclusive agreement signed on September 3, 2026.
